NVTA News
Archived Headlines
- Aced the gene test: Invitae prices upsized IPO above range at $16 02/11/15
- Week ahead: 12 IPOs feature health care, holdovers and a $500 million health tech IPO 02/09/15
- Know your genome: Invitae sets terms for $75 million IPO 02/02/15
- Genetic testing company Invitae files for an $86 million IPO 01/09/15
Genetic test firm AltheaDx passes on IPO: $60 million offering withdrawn
AltheaDx, which offers personalized genetic diagnostic tests to predict adverse drug reactions, withdrew its plans for an initial public offering on Monday. AltheaDx had originally filed to raise $60 million (4.6 million shares at $12-$14) in mid-February...read more
Deluge of genetic tests: RainDance Technologies files for a $60 million IPO
RainDance Technologies, which sells systems that perform non-invasive genetic analysis, filed on Friday with the SEC to raise up to $60 million in an initial public offering. Genetic testing companies have been active in the IPO market this year. Invitae...read more
US IPO Weekly Recap: No IPOs in final week of a challenging February
There were no initial public offerings in the past week, but recent IPO performance continues to trend up. The 24 IPOs in 2015 now average +18%, including +5% after the first day, its highest point this year. A few highlights from February 2015: ...read more
US IPO Weekly Recap: Big data produces small returns in a selective IPO market
Five companies had below-average returns and brought the number 2015 IPOs up to 22, a 39% decline from this time last year... IPO highlights during the week of February 9, 2015 ...read more